LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

21.2 0.76

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.13

Максимум

22.04

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+65.14% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-329M 2.6B
Предишно отваряне	20.44
Предишно затваряне	21.2

Настроения в новините

By Acuity

44%

56%

109 / 344 Класиране в Healthcare

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2026 г., 21:33 ч. UTC

Печалби

Correction to Salesforce 1Q Sales, Profit Rise Article

27.05.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Agrees to Buy The College of Health Care Professions

27.05.2026 г., 20:18 ч. UTC

Печалби

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27.05.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.05.2026 г., 23:08 ч. UTC

Пазарно говорене

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27.05.2026 г., 22:21 ч. UTC

Пазарно говорене

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27.05.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27.05.2026 г., 21:08 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27.05.2026 г., 21:02 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27.05.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27.05.2026 г., 20:55 ч. UTC

Печалби

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.05.2026 г., 20:48 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27.05.2026 г., 20:45 ч. UTC

Печалби

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27.05.2026 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Stockholders Approve Sale to Banco Santander

27.05.2026 г., 20:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27.05.2026 г., 20:30 ч. UTC

Печалби

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27.05.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27.05.2026 г., 20:22 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:16 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27.05.2026 г., 20:13 ч. UTC

Печалби

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

65.14% нагоре

12-месечна прогноза

Среден 34.86 USD 65.14%

Висок 36 USD

Нисък 34 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Настроение

By Acuity

109 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.